Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients (PROTEOHSEPS)
|ClinicalTrials.gov Identifier: NCT00930085|
Recruitment Status : Completed
First Posted : June 30, 2009
Last Update Posted : September 14, 2011
|Condition or disease||Intervention/treatment|
|Sepsis Septic Shock Cancer||Other: SELDI-TOF MS for plasmatic proteic profile|
Method: Monocentric prospective study with diagnostic and prognostic expectations.
Identification and characterization of early proteic biomarkers predictive of short term mortality in cancer patients with septic shock.
Research of clinical and biological prognostic factors.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients|
|Study Start Date :||August 2008|
|Primary Completion Date :||April 2011|
|Study Completion Date :||May 2011|
Experimental: SELDI-TOF MS
The proteic profiling is performed by SELDI-TOF mass spectroscopy.
Other: SELDI-TOF MS for plasmatic proteic profile
An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
- Identification and characterization of early proteic biomarkers predictive of short term mortality in cancer patients with septic shock. [ Time Frame: 1 month ]
- Research of clinical and biological prognostic factors. [ Time Frame: 1 month ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00930085
|Principal Investigator:||Djamel MOKART, MD||Institut Paoli-Calmettes|